CN115003794A - 治疗血管疾病的组合物和方法 - Google Patents

治疗血管疾病的组合物和方法 Download PDF

Info

Publication number
CN115003794A
CN115003794A CN202080075551.8A CN202080075551A CN115003794A CN 115003794 A CN115003794 A CN 115003794A CN 202080075551 A CN202080075551 A CN 202080075551A CN 115003794 A CN115003794 A CN 115003794A
Authority
CN
China
Prior art keywords
meso
cells
vpc
mir
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080075551.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·弥罗特索
N·普拉萨恩
A·辛格
R·兰沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Ocata Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocata Therapeutics Inc filed Critical Ocata Therapeutics Inc
Publication of CN115003794A publication Critical patent/CN115003794A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202080075551.8A 2019-08-28 2020-08-27 治疗血管疾病的组合物和方法 Pending CN115003794A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962892724P 2019-08-28 2019-08-28
US62/892,724 2019-08-28
PCT/US2020/048076 WO2021041591A1 (en) 2019-08-28 2020-08-27 Compositions and methods of treating vascular diseases

Publications (1)

Publication Number Publication Date
CN115003794A true CN115003794A (zh) 2022-09-02

Family

ID=72428364

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080075551.8A Pending CN115003794A (zh) 2019-08-28 2020-08-27 治疗血管疾病的组合物和方法

Country Status (13)

Country Link
US (1) US20220288131A1 (https=)
EP (1) EP4022038A1 (https=)
JP (2) JP2022545737A (https=)
KR (1) KR20220049618A (https=)
CN (1) CN115003794A (https=)
AU (1) AU2020337444A1 (https=)
BR (1) BR112022003659A2 (https=)
CA (1) CA3151636A1 (https=)
IL (1) IL290891A (https=)
MX (1) MX2022002418A (https=)
PH (1) PH12022550392A1 (https=)
TW (1) TW202122573A (https=)
WO (1) WO2021041591A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂
EP4372079A4 (en) * 2021-07-15 2025-07-30 Astellas Pharma Inc PERICYTE-LIKE CELLS EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AT A HIGH LEVEL
CN114231481B (zh) * 2021-12-21 2023-07-18 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法
US20240228975A9 (en) * 2022-07-19 2024-07-11 Lung Biotechnology Pbc Methods for Differentiating Endothelial Cells
CN118177150B (zh) * 2024-04-15 2024-12-03 中国医学科学院医学实验动物研究所 遗传多样性高血压小鼠模型的建立与基因转录调控分析

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064705A1 (en) * 2008-05-06 2011-03-17 Advanced Cell Technology, Inc. Hemangio colony forming cells and non-engrafting hemangio cells
US20110110853A1 (en) * 2008-06-30 2011-05-12 University College Cork, National University Of Ireland, Cork Primitive vascular progenitor cells and uses thereof
US20110305672A1 (en) * 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US20140045265A1 (en) * 2011-02-16 2014-02-13 Salk Institute For Biological Studies Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors
EP2718425A1 (en) * 2011-06-09 2014-04-16 F.Hoffmann-La Roche Ag Method for differentiation of pluripotent stem cells into vascular bed cells
EP2778223A1 (en) * 2011-11-08 2014-09-17 National University Corporation Nagoya University Vascular progenitor cell sheet derived from induced pluripotent stem cells, and production method therefor
WO2015153586A1 (en) * 2014-03-31 2015-10-08 The Johns Hopkins University Pluripotent stem cell therapies for ischemic retinopathies
WO2015172207A1 (en) * 2014-05-16 2015-11-19 Katholieke Universiteit Leuven Ku Leuven Research & Development Mesodermal progenitor cells
WO2016185457A1 (en) * 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
JP2017023019A (ja) * 2015-07-17 2017-02-02 国立大学法人京都大学 多能性幹細胞から中胚葉前駆細胞および血液血管前駆細胞への分化誘導法
CN109689858A (zh) * 2016-08-10 2019-04-26 印第安纳大学研究及科技有限公司 用于产生具有体内血管形成能力的中胚层和/或内皮集落形成细胞样细胞的方法
WO2019152483A1 (en) * 2018-01-30 2019-08-08 University Of Georgia Research Foundation, Inc. Methods for vascular construction and products therefrom

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434527A (zh) 2006-04-14 2017-02-22 安斯泰来再生医药协会 血管瘤集落形成细胞
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
SG11201706706XA (en) * 2015-02-20 2017-09-28 Wisconsin Alumni Res Found Generating arterial endothelial cell populations
JP6531335B2 (ja) * 2015-07-17 2019-06-19 国立大学法人京都大学 血管内皮細胞の誘導方法
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064705A1 (en) * 2008-05-06 2011-03-17 Advanced Cell Technology, Inc. Hemangio colony forming cells and non-engrafting hemangio cells
US20110110853A1 (en) * 2008-06-30 2011-05-12 University College Cork, National University Of Ireland, Cork Primitive vascular progenitor cells and uses thereof
US20110305672A1 (en) * 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US20140045265A1 (en) * 2011-02-16 2014-02-13 Salk Institute For Biological Studies Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors
EP2718425A1 (en) * 2011-06-09 2014-04-16 F.Hoffmann-La Roche Ag Method for differentiation of pluripotent stem cells into vascular bed cells
EP2778223A1 (en) * 2011-11-08 2014-09-17 National University Corporation Nagoya University Vascular progenitor cell sheet derived from induced pluripotent stem cells, and production method therefor
WO2015153586A1 (en) * 2014-03-31 2015-10-08 The Johns Hopkins University Pluripotent stem cell therapies for ischemic retinopathies
WO2015172207A1 (en) * 2014-05-16 2015-11-19 Katholieke Universiteit Leuven Ku Leuven Research & Development Mesodermal progenitor cells
WO2016185457A1 (en) * 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
JP2017023019A (ja) * 2015-07-17 2017-02-02 国立大学法人京都大学 多能性幹細胞から中胚葉前駆細胞および血液血管前駆細胞への分化誘導法
CN109689858A (zh) * 2016-08-10 2019-04-26 印第安纳大学研究及科技有限公司 用于产生具有体内血管形成能力的中胚层和/或内皮集落形成细胞样细胞的方法
WO2019152483A1 (en) * 2018-01-30 2019-08-08 University Of Georgia Research Foundation, Inc. Methods for vascular construction and products therefrom

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
HILL K 等: "Human embryonic stem cell-derived vascular progenitor cells capable of endothelial and smooth muscle cell function", 《EXP HEMATOL》, vol. 38, no. 3, 11 January 2010 (2010-01-11), pages 246 - 257 *
JAMES D 等: "Expansion and maintenance of human embryonic stem cell-derived endothelial cells by TGFbeta inhibition is Id1 dependent", 《NAT BIOTECHNOL》, vol. 28, no. 2, 17 January 2010 (2010-01-17), pages 161 - 166, XP002682519, DOI: 10.1038/NBT.1605 *
SONG W 等: "Efficient generation of endothelial cells from human pluripotent stem cells and characterization of their functional properties", 《J BIOMED MATER RES A》, vol. 104, no. 3, 14 November 2015 (2015-11-14), pages 678 - 687, XP055426277, DOI: 10.1002/jbm.a.35607 *
WANG L 等: "Human induced pluripotent stem cells derived endothelial cells mimicking vascular inflammatory response under flow", 《BIOMICROFLUIDICS》, vol. 10, no. 1, 13 January 2016 (2016-01-13), pages 1 - 13, XP055736650, DOI: 10.1063/1.4940041 *
ZHANG F 等: "Optimizing mesoderm progenitor selection and three-dimensional microniche culture allows highly efficient endothelial differentiation and ischemic tissue repair from human pluripotent stem cells", 《STEM CELL RES THER》, vol. 8, no. 1, 23 January 2017 (2017-01-23), pages 1 - 15 *
余元勋 等主编: "《中国分子白血病学》", vol. 2016, 30 April 2016, 安徽科学技术出版社, pages: 522 *
刘勇: "成人干细胞与血管再生疗法", 《生物医学工程与临床》, vol. 16, no. 6, 25 November 2012 (2012-11-25), pages 610 - 612 *
单长民 等主编: "《医用生物学实验与技术》", vol. 1999, 31 August 1999, 人民卫生出版社, pages: 88 - 89 *
李甜瑞 等: "类器官及其应用的研究进展", 《生物化学与生物物理进展》, vol. 46, no. 8, 20 August 2019 (2019-08-20), pages 737 - 750 *
王正国 等主编: "《分子创伤学》", vol. 2004, 31 August 2004, 福建科学技术出版社, pages: 538 - 540 *
罗纳德·布苏蒂尔 主编，夏强主译: "《肝移植 第3版》", vol. 2019, 31 January 2019, 上海科学技术出版社, pages: 1130 *

Also Published As

Publication number Publication date
JP2022545737A (ja) 2022-10-28
KR20220049618A (ko) 2022-04-21
TW202122573A (zh) 2021-06-16
BR112022003659A2 (pt) 2022-05-24
WO2021041591A1 (en) 2021-03-04
CA3151636A1 (en) 2021-03-04
AU2020337444A1 (en) 2022-03-24
MX2022002418A (es) 2022-03-22
PH12022550392A1 (en) 2022-12-19
IL290891A (en) 2022-04-01
JP2026001090A (ja) 2026-01-06
US20220288131A1 (en) 2022-09-15
EP4022038A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
CN115003794A (zh) 治疗血管疾病的组合物和方法
JP7333271B2 (ja) 心筋細胞の成熟および生着を増強するための方法および組成物
EP2900069B1 (en) Differentiation of human ips cells to human alveolar type ii via definitive endoderm
CN111630155B (zh) 胰岛细胞制备性组合物和使用方法
US20120295347A1 (en) Methods and Compositions for Producing Endothelial Progenitor Cells from Pluripotent Stem Cells
US20080194023A1 (en) Generating vascular smooth muscle cells in vitro from ES cells
CN116234819A (zh) 胰腺内分泌细胞的分化
JP6909230B2 (ja) 膵臓内分泌細胞の分化および精製のための方法
US20230030814A1 (en) Freeze-Dried Preparations Comprising Megakaryocytes and Platelets
KR101574659B1 (ko) 인간 다능성 줄기세포로부터의 인슐린 생산 베타 세포의 내분비 응집체의 제조 방법
EP4428227A1 (en) Production method for sheet-like retinal tissue
RU2843942C2 (ru) Композиции и способы лечения сосудистых заболеваний
Yang et al. Dead but functional liquid nitrogen‐treated umbilical cord mesenchymal stem cells accelerate full‐thickness skin wound healing
WO2022239868A1 (ja) 網膜組織の製造方法
US20110076254A1 (en) Porous scaffolds for stem cell renewal
HK40114369A (en) Production method for sheet-like retinal tissue
WO2024204596A1 (ja) 網膜組織の製造方法
HK40110173A (zh) 可生物降解的组织置换植入物及其用途
Glaser Defining the Microenvironment for Directing Embryonic Stem Cells into Endothelial Cells
Pilling Conversion of human fibroblasts to endothelial-like cells via dedifferentiation to mesodermal progenitors in 3D condensates
AU2008202264A1 (en) Novel Methods for the In-Vitro Indentification, Isolation and Differentiation of Vasculogenic Progenitor Cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination